Details of Ongoing Studies

www.clinicaltrials.gov

Outline of ongoing trials & major publications assessing effects of treatment of iron deficiency in chronic heart failure.

www.cardiometabolichealth.org

Outline of ongoing trials & major publications assessing effects of treatment of iron deficiency in chronic heart failure.

HEART-FID

n=3014

FAIR-HFpEF

n=200

FAIR-HF2

n=1200

Ponikowski et al. (AFFIRM-AHF)

van Veldhuisen et al. (EFFECT HF)

PREFFER-HF

n=72

van Veldhuisen et al. (EFFECT HF)

Lewis et al. (IRONOUT-HF)

Ponikowski et al. (CONFIRM-HF)

Beck-de-Silva et al. (IRON-HF)

Toblli et al.

Okonko et al. (FAIR-HF)

Anker et al. (FAIR-HF)

Okonko et al. (FAIR-HF)

PREFFER-HF

n=200

2017

2016

2014

2009

2007

n=72

n=200

n=1200

n=3014

Iron sucrose (i.v.) vs. ferrous sulfate (p.o.)

Iron sucrose (i.v.)

1. Intravenous, p.o.: per os.

6MWD: 6-Minute walk distance

12MWD: 12-Minute walk distance

*Ongoing trials are marked with an arrow

ADAPTED FROM:
- ClinicalTrials.gov

Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Mortality & Morbidity. FAIR-HF2, (n=1200) (NCT03036462)

STUDY

INCLUSION

IRON

OUTCOME

The Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: A Randomized, Open-label Multicenter Trial. IRONMAN, NCT03046256 (n=1299)

NYHA II-IV, LVEF <45%, Hb ≥9.0 g/dL and ≤13.0 g/dL (F) or ≤14.0 g/dL (M), ferritin <100 µg/L and/or TSAT <20% (with ferritin ≤400 µg/L), either HFH in 6 months or elevated NP

FCM (2 doses of 15 mg/kg to a max. individual dose of 750 mg, 7 days apart and a mass combined dose of 1,300 mg, repeated every 6 months) vs placebo

Death and HFH ≤1 year, and change in 6MWD at 6 months

Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: A Randomized, Open-label Multicenter Trial. IRONMAN, NCT03046256 (n=1299)

NYHA II-IV, LVEF <45%, Hb ≥9.0 g/dL and ≤13.0 g/dL (F) or ≤14.0 g/dL (M), ferritin <100 µg/L and/or TSAT <20% (with ferritin ≤400 µg/L), either HFH in 6 months or elevated NP

FCM (2 doses of 15 mg/kg to a max. individual dose of 750 mg, 7 days apart and a mass combined dose of 1,300 mg, repeated every 6 months) vs placebo

Death and HFH ≤1 year, and change in 6MWD at 6 months

Effect of IV Iron (Ferric Carboxymaltose) on Exercise Tolerance, Symptoms and Quality of Life in Patients With HFpEF and Iron Deficiency With or Without Anemia. FAIR-HFpEF

NCT03074591 (n=200)

HF with preserved LVEF (HFpEF) and diastolic dysfunction, LVEF ≥45%, NYHA II-III, either HFH within 1 year or elevated NP, Hb ≥9.0 g/dL and ≤14.0 g/dL, ferritin <100 µg/L, or ferritin 100-299 with TSAT <20%, 6MWD <450 m

FCM vs placebo

Exercise capacity: change in 6MWD from baseline to 12 months

FAIR-HFpEF

Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: A Randomized, Open-label Multicenter Trial. IRONMAN, NCT03046256 (n=1299)

NYHA II-IV, LVEF <45%, Hb ≥9.0 g/dL and ≤13.0 g/dL (F) or ≤14.0 g/dL (M), ferritin <100 µg/L and/or TSAT <20% (with ferritin ≤400 µg/L), either HFH in 6 months or elevated NP

FCM (2 doses of 15 mg/kg to a max. individual dose of 750 mg, 7 days apart and a mass combined dose of 1,300 mg, repeated every 6 months) vs placebo

Death and HFH ≤1 year, and change in 6MWD at 6 months

Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: A Randomized, Open-label Multicenter Trial. IRONMAN, NCT03046256 (n=1299)

NYHA II-IV, LVEF <45%, Hb ≥9.0 g/dL and ≤13.0 g/dL (F) or ≤14.0 g/dL (M), ferritin <100 µg/L and/or TSAT <20% (with ferritin ≤400 µg/L), either HFH in 6 months or elevated NP

FCM (2 doses of 15 mg/kg to a max. individual dose of 750 mg, 7 days apart and a mass combined dose of 1,300 mg, repeated every 6 months) vs placebo

Death and HFH ≤1 year, and change in 6MWD at 6 months

Effect of IV Iron (Ferric Carboxymaltose) on Exercise Tolerance, Symptoms and Quality of Life in Patients With HFpEF and Iron Deficiency With or Without Anemia. FAIR-HFpEF

NCT03074591 (n=200)

HF with preserved LVEF (HFpEF) and diastolic dysfunction, LVEF ≥45%, NYHA II-III, either HFH within 1 year or elevated NP, Hb ≥9.0 g/dL and ≤14.0 g/dL, ferritin <100 µg/L, or ferritin 100-299 with TSAT <20%, 6MWD <450 m

FCM vs placebo

Exercise capacity: change in 6MWD from baseline to 12 months

HEART-FID

n=3014

PREFFER-HF

n=200

FAIR-HF2

n=1200

Ponikowski et al. (AFFIRM-AHF)

van Veldhuisen et al. (EFFECT HF)

Lewis et al. (IRONOUT-HF)

Ponikowski et al. (CONFIRM-HF)

Beck-de-Silva et al. (IRON-HF)

Toblli et al.

Okonko et al. (FAIR-HF)

Anker et al. (FAIR-HF)